210 related articles for article (PubMed ID: 33051428)
1. New approaches in chimeric antigen receptor T-cell therapy for breast cancer.
Zhang Q; Ding B; Qian L; Wu W; Wen Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 Sept 28; 45(9):1120-1126. PubMed ID: 33051428
[TBL] [Abstract][Full Text] [Related]
2. Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy.
Luangwattananun P; Junking M; Sujjitjoon J; Wutti-In Y; Poungvarin N; Thuwajit C; Yenchitsomanus PT
Breast Cancer Res Treat; 2021 Feb; 186(1):25-36. PubMed ID: 33389403
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor-based immunotherapy in breast cancer: Recent progress in China.
Yu T; Lu Y; Fang J; Jiang X; Lu Y; Zheng J; Shang X; Shen H; Fu P
Cancer; 2024 Apr; 130(S8):1378-1391. PubMed ID: 37950749
[TBL] [Abstract][Full Text] [Related]
4. Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer.
Cao Y; Efetov SK; He M; Fu Y; Beeraka NM; Zhang J; Zhang X; Bannimath N; Chen K
Arch Immunol Ther Exp (Warsz); 2023 Aug; 71(1):19. PubMed ID: 37566162
[TBL] [Abstract][Full Text] [Related]
5. Advances in chimeric antigen receptor T cells therapy in the treatment of breast cancer.
He Q; Hu H; Yang F; Song D; Zhang X; Dai X
Biomed Pharmacother; 2023 Jun; 162():114609. PubMed ID: 37001182
[TBL] [Abstract][Full Text] [Related]
6. New Approaches in CAR-T Cell Immunotherapy for Breast Cancer.
Wang J; Zhou P
Adv Exp Med Biol; 2017; 1026():371-381. PubMed ID: 29282693
[TBL] [Abstract][Full Text] [Related]
7. [Chimeric antigen receptor T cell (CAR-T) therapy for refractory/relapsed hematological malignancy].
Hiramatsu H
Rinsho Ketsueki; 2018; 59(10):1948-1954. PubMed ID: 30305496
[TBL] [Abstract][Full Text] [Related]
8. The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook.
Zhang H; Zhu S; Deng W; Li R; Zhou H; Xiong H
Front Immunol; 2022; 13():887471. PubMed ID: 35935930
[TBL] [Abstract][Full Text] [Related]
9. [Specific cytotoxicity of a novel HER2-based chimeric antigen receptor modified T lymphocytes against HER2-positive tumor cells].
Tang HJ; Liu YQ; Bian XC; Feng HL; Gu B; Sun H; Zuo CX; Zhou FY; Liu J
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):714-720. PubMed ID: 29050075
[No Abstract] [Full Text] [Related]
10. CAR-T Cell Therapy for Breast Cancer: From Basic Research to Clinical Application.
Yang YH; Liu JW; Lu C; Wei JF
Int J Biol Sci; 2022; 18(6):2609-2626. PubMed ID: 35414783
[TBL] [Abstract][Full Text] [Related]
11. [Progression in chimeric antigen receptor T (CAR-T) cell therapy of solid tumors: A review].
Fang Z; Han H; Liang L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2019 Oct; 35(10):944-948. PubMed ID: 31814572
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for lung cancer: Focusing on chimeric antigen receptor (CAR)-T cell therapy.
Xue T; Zhao X; Zhao K; Lu Y; Yao J; Ji X
Curr Probl Cancer; 2022 Feb; 46(1):100791. PubMed ID: 34538649
[TBL] [Abstract][Full Text] [Related]
13. [Cell therapy's poster child: Chimeric antigen receptor T cell therapy].
Qian L; Chen J; Wu X; Jing R; Sun J
Sheng Wu Gong Cheng Xue Bao; 2019 Dec; 35(12):2339-2349. PubMed ID: 31880140
[TBL] [Abstract][Full Text] [Related]
14. Advances in natural killer cell therapies for breast cancer.
Kiaei SZF; Nouralishahi A; Ghasemirad M; Barkhordar M; Ghaffari S; Kheradjoo H; Saleh M; Mohammadzadehsaliani S; Molaeipour Z
Immunol Cell Biol; 2023 Sep; 101(8):705-726. PubMed ID: 37282729
[TBL] [Abstract][Full Text] [Related]
15. Emerging Immunotherapies against Novel Molecular Targets in Breast Cancer.
Sivaganesh V; Promi N; Maher S; Peethambaran B
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33670942
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic adenovirus targeting TGF-β enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer.
Li Y; Xiao F; Zhang A; Zhang D; Nie W; Xu T; Han B; Seth P; Wang H; Yang Y; Wang L
Cell Immunol; 2020 Feb; 348():104041. PubMed ID: 31983398
[TBL] [Abstract][Full Text] [Related]
18. Cell Therapies in Bladder Cancer Management.
Morales L; Paramio JM
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802203
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
Siegler EL; Wang P
Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]